Lenco Diagnostic Laboratory Services | Medical Diagnostic Laboratories NYC

Important Links and Updates about COVID-19

Click here for information on COVID-19 testing Click here for information on Antibody testing for COVID-19

Important Links
and Updates about
COVID-19

Click here
for information on
COVID-19 testing Click here
for information on
Antibody testing for COVID-19

We provide the most comprehensive COVID-19 testing solutions to support your organizations in safely reopening and getting back to business.

Reopening and Resuming Operations – Comprehensive COVID-19 Testing

No one knows exactly what the world would look like after COVID-19. Lenco is here to help mitigate the risk of exposing employees, customers and your community to SARS-CoV-2. We provide the most comprehensive COVID-19 testing solutions to support your organizations in safely reopening and getting back to business.

Beckman Coulter's SARS-CoV-2 IgG II antibody test receives Emergency Use Authorization from the FDA

Beckman Coulter's SARS-CoV-2 IgG II antibody test receives Emergency Use Authorization from the FDA

BREA, Calif., March 23, 2021 /PRNewswire/ -- Beckman Coulter, a clinical diagnostics leader, announced that its Access SARS-CoV-2 IgG II antibody assay received U.S. Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration.

Lenco Diagnostic Laboratories Offers Serology Testing to Detect Antibodies Against COVID-19

Lenco Diagnostic Laboratories Offers Serology Testing to Detect Antibodies Against COVID-19

Lenco performs serology tests that will be used to detect antibodies through blood against SARS-CoV-2 virus that causes COVID-19 infection.

Lenco Diagnostic Laboratories offers options for COVID-19 testing to meet the urgent needs of New Yorkers during this public healthcare crisis.

Lenco Diagnostic Laboratories offers options for COVID-19 testing to meet the urgent needs of New Yorkers during this public healthcare crisis.

Lenco performs high-throughput, automated Real-Time RT-PCR diagnostic testing intended for the qualitative detection of COVID-19.

Excellence is in Our DNA

Excellence is in Our DNA

Our secret to success lies in our people: Lenco’s team of highly-dedicated specialists possess expert credentials, unparalleled experience, and the most effective professionalism in the industry today. Our commitment to providing high-quality services, with patient’s needs as the highest priority, puts us at the cutting edge of diagnostics.

Shaping the Future of Clinical Diagnostics

Shaping the Future of Clinical Diagnostics

Founded in 2002, Lenco Diagnostic Laboratories, Inc. offers unmatched clinical diagnostic services and state-of-the-art technology. Our commitment to excellence is obtained through tireless technological innovation. As a full-service clinical reference laboratory, renowned for excellence and expertise, we continuously engage in meeting the needs of physicians, clients, and their patients.

Customer Service Second-to-None

Customer Service Second-to-None

We set the industry standard for customer service with:

The best turnaround times in diagnostics
Our first-time-right service, every time
Our state-of-the-art IT Department enables clients with secure internet access to patient results anywhere and at any time

Our customer care team of friendly, polite and experienced staff ensures that all queries are answered quickly – putting an end to button-pushing and long, frustrating waits on the phone.

Why Us?

Unlike other laboratories, Lenco’s services are tailormade specific to the needs of every client. We offer follow-up, face-to-face consultations and customer support to help our clients grow their practices and provide their patients with the best possible care. We are dedicated to always going an extra mile by combining our lateral thinking abilities, cutting-edge technology, and high-standard professionalism.

Lenco is pleased to announce that COVID-19 testing sites have opened throughout New York as part of the NY Forward initiative.

Lenco Diagnostic Laboratories has partnered with New York State’s Excelsior Pass, a free, secure & easy digital tool New Yorkers can use to verify their COVID-19 vaccination or negative test results to gain entry to major stadiums and arenas, wedding receptions, or catered and other events in accordance with New York State guidelines. As part of this partnership, we are expediting reporting of test results to ensure you receive them in a timely manner. Learn more about Excelsion Pass by clicking here.

Be a part of New York’s safe reopening! https://covid19vaccine.health.ny.gov/excelsior-pass

What We Do

Lenco Diagnostic Laboratories provides reference testing and specialty diagnostic testing to thousands of patients a day. From simple blood counts to genetic testing for rare diseases, Lenco's diversity of diagnostic tests is facilitated by state-of-the-art equipment that sets the status quo in a world of rapidly advancing diagnostic technology. This has allowed Lenco to provide superior testing and highly competitive result turn-around times, among the best in the industry. Lenco's Patient Service Centers and Mobile Laboratory Vans have access to the same standard of diagnostic testing capabilities, helping Lenco provide high quality laboratory services to patients and healthcare providers alike.

College of American Pathologists

Lenco Diagnostic Laboratories
is accredited by the College of American Pathologists

Lenco Diagnostic Laboratories
is accredited by the College of American Pathologists

Lenco Diagnostic Laboratory in 'PR Newswire' for successful COVID-19 testing program with CGM

Lenco Diagnostic Laboratory in 'PR Newswire' for successful COVID-19 testing program with CGM

Lenco Laboratories recently appeared in PR Newswire for its partnership with CompuGroup Medical in launching a successful COVID-19 testing program:

The leading global healthcare technology company, CompuGroup Medical (CGM), assisted Lenco Diagnostic Laboratory (Lenco) with the launch of its successful COVID-19 testing program on March 19. Since then, Lenco has delivered test results for thousands of New Yorkers every day.

"In the month of July, we ran 49,788 COVID-19 PCR tests on patients from doctors' offices, nursing homes, and local hospitals," said Felix Sandler, Chief Information Officer of Lenco. "CGM was instrumental in quickly setting up instrument interfaces and resolving any production issues to facilitate the rapid ramp-up of testing."

Lenco Diagnostic Laboratories Provides Update on Its Recent COVID-19 and IgG and IgM Serology Testing

Lenco Diagnostic Laboratories Provides Update on Its Recent COVID-19 and IgG and IgM Serology Testing

Lenco Diagnostic Laboratories (Lenco), one of NYC's largest privately-owned full service reference laboratories, provides an update on COVID-19 testing and recently launched IgG and IgM serology testing to detect antibodies against COVID-19.

In mid-March, Lenco became one of the first 28 approved New York laboratories to start testing for COVID-19 with a molecular based assay utilizing PCR technology for the qualitative detection of nucleic acid in respiratory specimens in patients who meet the Centers for Disease Control and Prevention criteria.

Lenco Diagnostic Laboratories Launches IgG and IgM Serology Testing to Detect Antibodies Against COVID-19

Lenco Diagnostic Laboratories Launches IgG and IgM Serology Testing to Detect Antibodies Against COVID-19

Brooklyn, NY (April 16, 2020) - Lenco Diagnostic Laboratories (Lenco), one of NYC's largest independently owned full-service clinical laboratories, today announced the launch of antibody testing for coronavirus (COVID-19).

“In the last several weeks, Lenco has been diligently working with trusted partners to launch a test that will detect the presence of IgG and IgM antibodies produced by the body in response to the SARS-CoV-2 virus,” stated Dennis Tilman, Chief Operating Officer of Lenco. “We are hopeful the knowledge obtained from these tests will help both physicians and patients in the management and care of this novel virus. Lenco is proud to expand its diagnostic capabilities and will continue to contribute to the needs of the community.”

Lenco Diagnostic Laboratories to Launch IgG and IgM Serology Testing to Detect Antibodies Against COVID-19

Lenco Diagnostic Laboratories to Launch IgG and IgM Serology Testing to Detect Antibodies Against COVID-19

Brooklyn, NY (April 14, 2020) - Lenco Diagnostic Laboratories (Lenco), one of NYC's largest independently owned full service clinical laboratories, today announced it is currently working with trusted manufacturing partners to launch IgG and IgM serology tests that will be used to detect antibodies through blood against SARS-CoV-2 virus that causes COVID-19 infection.

Beckman Coulter, Lenco Diagnostic Laboratories deliver more than 20,000 highly accurate COVID-19 antibody tests each week to New York City

Beckman Coulter, Lenco Diagnostic Laboratories deliver more than 20,000 highly accurate COVID-19 antibody tests each week to New York City

BROOKLYN, N.Y., July 6, 2020 /PRNewswire/ -- Beckman Coulter and Lenco Diagnostic Laboratories (Lenco), one of NYC's largest privately-owned full-service reference laboratories, today announced that the first shipment of 40,000 of Beckman Coulter's new Access SARS-CoV-2 IgG Antibody tests has arrived in New York City to help battle the COVID-19 outbreak, with 20,000 additional tests anticipated each week.

Lenco was among the first clinical labs to receive a shipment of the new Beckman Coulter SARS-CoV-2 IgG antibody test. The Beckman Coulter COVID-19 serology test is one of the most accurate and high-quality tests available in the U.S., and has 100% Positive Percent Agreement (sensitivity) and a confirmed 99.6% Negative Percent Agreement (specificity).

Lenco Diagnostic Laboratories Has Launched Coronavirus 2019 (COVID-19) Testing

Lenco Diagnostic Laboratories Has Launched Coronavirus 2019 (COVID-19) Testing

Brooklyn, NY (March 20, 2020) - Lenco Diagnostic Laboratories (Lenco), one of NYC's largest independently owned full service clinical laboratories, has launched testing for coronavirus (COVID-19).

Lenco performs high-throughput, automated Real-Time RT-PCR diagnostic testing intended for the qualitative detection of COVID-19. This test is to be performed only using respiratory specimens collected from individuals who meet COVID-19 clinical and/or epidemiological criteria for testing.

Lenco Diagnostic Laboratories to Launch Coronavirus Disease 2019 (COVID-19) Test

Lenco Diagnostic Laboratories to Launch Coronavirus Disease 2019 (COVID-19) Test

Brooklyn, NY (March 9, 2020) - Lenco Diagnostic Laboratories (Lenco), one of NYC’s largest privately-owned full service reference laboratories, announced it is currently working with trusted manufacturing partners to launch a new coronavirus disease 2019 (COVID-19) test. The test will aid in detection of the underlying novel coronavirus that causes COVID-19 and will be used with patients who meet the Centers for Disease Control and Prevention (CDC) clinical criteria for testing.

Novel coronavirus has been identified as the cause of a disease outbreak in Wuhan, China. COVID-19, causing pneumonia-like symptoms, can spread from person to person. The risk of infection for COVID-19 is higher for older adults and those who have serious chronic medical conditions. The virus can easily be transmitted between people as close as six feet within distance of each other through respiratory droplets produced when coughing or sneezing.

Subscribe to
Get Our Latest News!